Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Conditions
- Lung Non-Small Cell Carcinoma
- Stage IIIB Lung Cancer AJCC v8
- Stage IV Lung Cancer AJCC v8
Interventions
- DRUG: Adagrasib
- BIOLOGICAL: Anti-PD-L1 Monoclonal Antibody
- BIOLOGICAL: Anti-PD1 Monoclonal Antibody
- BIOLOGICAL: Bevacizumab
- PROCEDURE: Biopsy Procedure
- PROCEDURE: Biospecimen Collection
- DRUG: Chemotherapy
- PROCEDURE: Computed Tomography
- BIOLOGICAL: Durvalumab
- PROCEDURE: Magnetic Resonance Imaging
- OTHER: Monitoring
- PROCEDURE: Positron Emission Tomography
- BEHAVIORAL: Surveillance
- BIOLOGICAL: Tremelimumab
Sponsor
City of Hope Medical Center
Collaborators